Exhibit 99.1 IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense in breast cancer indication CAESAREA, Israel, April 3, 2024 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSen ...